Progression of chronic kidney disease: Can it be prevented or arrested?

American Journal of Medicine

Volumn 118, Issue 12, 2005, Pages 1323-1330

  Jaber, Bertrand L ^a,b   Madias, Nicolaos E ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

ACE inhibitors; Aldosterone; Angiotensin receptor blockers; Cytokines; Diabetic nephropathy; End stage renal disease; Endothelin; Hypertension; Proteinuria; Renin angiotensin system; Statins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSTERONE ANTAGONIST; ALPHA GALACTOSIDASE; AMINOGUANIDINE; ANTIFIBROTIC AGENT; ANTIOXIDANT; BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GLYCOSAMINOGLYCAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; VASOPRESSIN ANTAGONIST;

ANEMIA; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME REPLACEMENT; FABRY DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY POLYCYSTIC DISEASE; LIFESTYLE; MEMBRANOUS GLOMERULONEPHRITIS; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING CESSATION; SODIUM RESTRICTION;

ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CHRONIC DISEASE; CYTOKINES; DIABETIC NEPHROPATHIES; DIET; DISEASE PROGRESSION; ENZYMES; GENE THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; PHARMACOGENETICS; PROTEINURIA; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 29244448682     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.02.032     Document Type: Review

References (80)

1. United States Renal Data System 2003 National Institutes of Health, Diabetes and Digestive and Kidney Diseases Bethesda, MD. Annual Data Report
2. E. Young, D. Goodkin, D. Mapes The Dialysis Outcomes and Practice Patterns Study (DOPPS) an international hemodialysis study Kidney Int 57 suppl 74 2000 S74 S81
3. D. Goodkin, J. Bragg-Gresham, K. Koenig Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States the Dialysis Outcomes and Practice Patterns Study (DOPPS) J Am Soc Nephrol 14 2003 3270 3277
4. S. Klahr, A.S. Levey, G. Beck the Modification of Diet in Renal Disease Study Group The effect of dietary protein restriction and blood-pressure control on the progression of chronic renal disease N Engl J Med 330 1994 877 884
5. B. Brenner Retarding the progression of renal disease Kidney Int 64 2003 370 378
6. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde Collaborative Study Group The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
7. E. Lewis, L. Hunsicker, W. Clarke Collaborative Study Group renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
8. B. Brenner, M. Cooper, D. de Zeeuw RENAAL Study Investigators effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
9. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 1997 1857 1863
10. I. Giatras, J. Lau, A.S. Levey Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease a meta-analysis of randomized trials Ann Intern Med 127 1997 337 345
11. T.H. Jafar, C.H. Schmid, M. Landa Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data Ann Intern Med 135 2001 73 87
12. T. Jafar, C. Schmid, A. Levey Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease Ann Intern Med 137 2002 298 299
13. H. Parving, A. Andersen, U. Smidt, E. Hommel, E. Mathiesen, P. Svendsen Effect of antihypertensive treatment on kidney function in diabetic nephropathy BMJ 294 1987 1443 1447
14. H. Parving, E. Hommel, U. Smidt Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy BMJ 297 1988 1086 1091
15. H. Parving, E. Hommel, M. Damkjaer Nielsen, J. Giese Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy BMJ 299 1989 533 536
16. R. Toto Hypertensive nephrosclerosis in African Americans Kidney Int 64 2003 2331 2341
17. R. Toto, H. Mitchell, R. Smith, H. Lee, D. McIntire, W. Pettinger Strict blood pressure control and progression of renal disease in hypertensive nephrosclerosis Kidney Int 48 1995 851 859
18. J.J. Wright, G. Bakris, T. Greene African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease results from the AASK trial JAMA 288 2002 2421 2431
19. A. Schieppati, G. Remuzzi The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises Kidney Int 64 2003 1947 1955
20. H. Sollinger U.S. Renal Transplant Mycophenolate Mofetil Study Group Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients Transplantation 60 1995 225 232
21. T. Chan, F. Li, C. Tang, R. Wong The Hong Kong Guangzhou Nephrology Study Group efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis N Engl J Med 343 2000 1156 1162
22. G. Contreras, V. Pardo, B. Leclercq Sequential therapies for proliferative lupus nephritis N Engl J Med 350 2004 971 980
23. K. Saito, M. Nawata, S. Nakayamada, M. Tokunaga, J. Tsukada, Y. Tanaka Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement Lupus 12 2003 798 800
24. G. Fra, G. Avanzi, E. Bartoli Remission of refractory lupus nephritis with a protocol including rituximab Lupus 12 2003 783 787
25. R. Looney, J. Anolik, I. Sanz B lymphocytes in systemic lupus erythematosus lessons from therapy targeting B cells Lupus 13 2004 381 390
26. G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli, P. Ruggenenti Rituximab for idiopathic membranous nephropathy Lancet 360 2002 923 924
27. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
28. P. Fioretto, M. Steffes, D. Sutherland, F. Goetz, M. Mauer Reversal of lesions of diabetic nephropathy after pancreas transplantation N Engl J Med 339 1998 69 75
29. M.E. Williams New therapies for advanced glycation end product nephrotoxicity current challenges Am J Kidney Dis 41 3 Suppl 1 2003 S42 S47
30. W. Bolton, D. Cattran, M. Williams ACTION I Investigator Group randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy Am J Nephrol 24 2004 32 40
31. E. Avner, R. Woychik, K. Dell, W. Sweeney Cellular pathophysiology of cystic kidney disease insight into future therapies Int J Dev Biol 43 1999 457 461
32. V.H. Gattone 2nd, X. Wang, P.C. Harris, V.E. Torres Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist Nat Med 9 2003 1323 1326
33. K. Siamopoulos Fabry disease kidney involvement and enzyme replacement therapy Kidney Int 65 2004 744 753
34. National Kidney Foundation K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 Suppl 5 2004 1 268
35. R.O. Estacio, B.W. Jeffers, N. Gifford Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 Suppl 2 2000 B54 B64
36. A. Fogo Progression and potential regression of glomerulosclerosis Kidney Int 59 2001 804 819
37. H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, P. Arner Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
38. D. Russo, A. Pisani, M. Balletta Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy Am J Kidney Dis 33 1999 851 856
39. N. Nakao, A. Yoshimura, H. Morita, M. Takada, T. Kayano, T. Ideura Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) a randomised controlled trial Lancet 361 2003 117 124
40. P. Jacobsen, S. Andersen, K. Rossing, B. Jensen, H. Parving Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy Kidney Int 63 2003 1874 1880
41. J. Serratrice, B. Granel, P. Disdier, P. Weiller, B. Dussol Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still's disease Am J Med 115 2003 589 590
42. G.M. Doherty, J.C. Jensen, H. Alexander, C.M. Buresh, J.A. Norton Pentoxifylline suppression of tumor necrosis factor gene transcription Surgery 110 1991 192 198
43. S. Lin, Y. Chen, C. Chien, W. Chiang, C. Tsai, T. Tsai Pentoxifylline attenuated the renal disease progression in rats with remnant kidney J Am Soc Nephrol 13 2002 2916 2929
44. J. Navarro, C. Mora, M. Muros, M. Maca, J. Garca Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients a short-term, prospective, randomized study Am J Kidney Dis 42 2003 264 270
45. A. Fogo Renal fibrosis not just PAI-1 in the sky J Clin Invest 112 2003 326 328
46. A. Zhou, H. Ueno, M. Shimomura Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis Kidney Int 64 2003 92 101
47. Y. Huang, M. Haraguchi, D. Lawrence, W. Border, L. Yu, N. Noble A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis J Clin Invest 112 2003 379 388
48. A. Chrysostomou, G. Becker Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease N Engl J Med 345 2001 925 926
49. A. Cosenzi, E. Bernobich, R. Trevisan, N. Milutinovic, A. Borri, G. Bellini Nephroprotective effect of bosentan in diabetic rats J Cardiovasc Pharmacol 42 2003 752 756
50. J. Simons, A. Provoost, S. Anderson, H. Rennke, J. Troy, B. Brenner Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury Kidney Int 46 1994 396 404
51. C. Zoja, A. Benigni, D. Camozzi Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis Kidney Int 64 2003 857 863
52. M. Taal, V. Nenov, W. Wong Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone J Am Soc Nephrol 12 2001 2051 2059
53. P. Gaede, H. Poulsen, H. Parving, O. Pedersen Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients Diabet Med 18 2001 756 760
54. C. Zoja, D. Corna, D. Rottoli Effect of combining ACE inhibitor and statin in severe experimental nephropathy Kidney Int 61 2002 1635 1645
55. A. Kolyada, A. Fedtsov, N. Madias 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells Hypertension 38 2001 1024 1029
56. L. Blanco-Colio, J. Tunon, J. Martin-Ventura, J. Egido Anti-inflammatory and immunomodulatory effects of statins Kidney Int 63 2003 12 23
57. L. Fried, T. Orchard, B. Kasiske The effect of lipid reduction on the progression of renal disease a meta-analysis Kidney Int 59 2001 260 269
58. C. Zoja, D. Corna, D. Camozzi How to fully protect the kidney in a severe model of progressive nephropathy a multidrug approach J Am Soc Nephrol 13 2002 2898 2908
59. P. Ruggenentia, A. Schieppatib, G. Remuzzi Progression, remission, regression of chronic renal diseases Lancet 357 2001 1601 1608
60. G. Gambaro, B. Baggio Glycosaminoglycans a new paradigm in the prevention of proteinuria and progression of glomerular disease Nephrol Dial Transplant 11 1996 762 764
61. G. Gambaro, I. Kinalska, A. Oksa Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients the Di.N.A.S. randomized trial J Am Soc Nephrol 13 2002 1615 1625
62. P. Deepa, P. Varalakshmi The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity Eur J Pharmacol 478 2003 199 205
63. N. Clyne, J. Ekholm, T. Jogestrand, L. Lins, S. Pehrsson Effects of exercise training in predialytic uremic patients Nephron 59 1991 84 89
64. D. Roth, R. Smith, G. Schulman Effects of recombinant human erythropoietin on renal function in chronic renal failure pre-dialysis patients Am J Kidney Dis 24 1994 777 784
65. S. Kuriyama, H. Tomonari, H. Yoshida, T. Hashimoto, Y. Kawaguchi, O. Sakai Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients Nephron 77 1997 177 185
66. C. Gouva, P. Nikolopoulos, J. Ioannidis, K. Siamopoulos Treating anemia early in renal failure patients slows the decline of renal function a randomized controlled trial Kidney Int 66 2004 753 760
67. F.M. Sacks, L.P. Svetkey, W.M. Vollmer DASH-Sodium Collaborative Research Group Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet N Engl J Med 344 2001 3 10
68. M. Pedrini, A. Levey, J. Lau, T. Chalmers, P. Wang The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases a meta-analysis Ann Intern Med 124 1996 627 632
69. S. Orth, E. Ritz, R. Schrier The renal risks of smoking Kidney Int 51 1997 1669 1677
70. B. Stengel, M. Tarver-Carr, N. Powe, M. Eberhardt, F. Brancati Lifestyle factors, obesity and the risk of chronic kidney disease Epidemiology 14 2003 479 487
71. R. Sung, M. Althoen, T. Howell, A. Ojo, R. Merion Excess risk of renal allograft loss associated with cigarette smoking Transplantation 71 2001 1752 1757
72. H. Parving, P. Jacobsen, L. Tarnow Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme observational follow up study BMJ 313 1996 591 594
73. P. Jacobsen, L. Tarnow, B. Carstensen, P. Hovind, O. Poirier, H. Parving Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy J Am Soc Nephrol 14 2003 2843 2850
74. T. Wong, P. Poon, C. Szeto, J. Chan, P. Li Association of plasminogen activator inhibitor-14G/4G genotype and type 2 diabetic nephropathy in Chinese patients Kidney Int 57 2000 632 638
75. T. Wong, P. Poon, K. Chow, C. Szeto, M. Cheung, P. Li Association of transforming growth factor-beta (TGF-beta) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese Kidney Int 63 2003 1831 1835
76. M. Adamczak, M. Gross, J. Krtil Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats J Am Soc Nephrol 14 2003 2833 2842
77. E. Mathiesen, E. Hommel, H. Hansen, U. Smidt, H. Parving Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria BMJ 319 1999 24 25
78. P. Hovind, P. Rossing, L. Tarnow, H. Toft, J. Parving, H. Parving Remission of nephrotic-range albuminuria in type 1 diabetic patients Diabetes Care 24 2001 1972 1977
79. S. Andersen, J. Brochner-Mortensen, H. Parving Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria Diabetes Care 26 2003 3296 3302
80. P. Gaede, P. Vedel, N. Larsen, G. Jensen, H. Parving, O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393